Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: Results from the French haemophilia cohort

British Journal of Haematology

Volumn 116, Issue 2, 2002, Pages 383-389

  Costagliola, Dominique ^a   Potard, Valérie ^a   Tahiri, Cedric ^a   Gaboulaud, Valérie ^a   Parquet, Armelle ^b   Claeyssens, Ségolène ^c   Faradji, Albert ^d  

^a INSERM   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c CHU PURPAN   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Clotting factor concentrates; Haemophilia; Human parvovirus B19; Recombinant FVIII; Viral safety

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DETERGENT; F VII THP SD; FIX HP SD; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; SOLVENT;

ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG PURIFICATION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEMOPHILIA; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NANOFILTRATION; PARVOVIRUS; PLASMA; PLASMA TRANSFUSION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANTIBODIES, VIRAL; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN G; INFANT; LOGISTIC MODELS; MALE; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 0036175016     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1048.2001.03293.x     Document Type: Article

References (33)

1. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A
2. Human parvovirus B19 infection in haemophiliacs first infused with two high-purity, virally atenuated factor VIII concentrates
3. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates
4. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
5. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates
6. The French haemophilia cohort: Rationale and organisation of a long-term national pharmacosurveillance system
7. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: Protection of proteins by antioxidants
8. Parvovirus B19: An expanding spectrum of disease
9. Severe parvovirus B19 infection in an immunocompetent hemophiliac A child
10. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products
11. The prevalence of antibody to parvovirus B19 in hemophiliacs and the general population
12. Parvovirus B19 DNA contamination in coagulation factor VIII products
13. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses
14. Serological and virological markers of human parvovirus b19 infection in sera of hemophiliacs
15. A synthetic B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassays
16. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates
17. Viral safety and clotting factor concentrates
18. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates
19. Albumin batches and B19 parvovirus DNA
20. A review of goodness of fit statistics for use in the development of logistic regression models
21. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A
22. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate
23. Detection of parvovirus B19 in donated blood: A model system for screening by polymerase chain reaction
24. Transmission of serum parvovirus-like virus by clotting factor concentrates
25. Persistent B19 parvovirus infections in haemophilic HIV-1 infected patients
26. Parvovirus B19 antibodies in patients with haemophilia A
27. Human parvovirus B19 infection in persons with haemophilia
28. Parvovirus B19 infection in patients with hemophilia
29. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implications for efficiency and consistency of removal of B19 DNA during manufacture
30. Removal of parvovirus B19 from contaminated factor VIII during fractionation
31. Transmission of human parvovirus B19 by coagulation factor concentrates
32. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate
33. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction